Status:
COMPLETED
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
University of Virginia
Conditions:
PCOS
Eligibility:
FEMALE
12-18 years
Phase:
PHASE3
Brief Summary
In women with polycystic ovary syndrome (PCOS), the cardinal physiological abnormality is excessive ovarian androgen production marked by increased serum testosterone (T) and androstenedione (A) level...
Detailed Description
In women with polycystic ovary syndrome (PCOS), the cardinal physiological abnormality is excessive ovarian androgen production marked by increased serum testosterone (T) and androstenedione (A) level...
Eligibility Criteria
Inclusion
- Normal CBC (Hemoglobin must be at least 11mg/dl)
- Normal renal and liver function tests
- Normal vital signs including normal blood pressure
Exclusion
- Pregnancy
- On oral contraceptives
- On insulin lowering drugs
- On anti-androgens (i.e., spironolactone, flutamide, finasteride, etc)
- On medications that will influence androgen metabolism or clearance
- On medications that will inhibit the cytochrome P450 enzyme system (Cimetidine, ketoconazole, etc)
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01154192
Start Date
August 1 2011
End Date
September 1 2014
Last Update
April 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD School of Medicine
La Jolla, California, United States, 92093